RIGL Rigel Pharmaceuticals Inc

For the fiscal year ended 31/12/2022: Rigel Pharmaceuticals Inc's revenues decreased by 19.43% and amounted to 120.24M. Net income decreased by 226.97% to -58.57M. Net assets decreased by 144.83% to -13.62M and EPS decreased from -0.11 to -0.34.